Mechanisms of resistance to anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer

Table 2 Single nuclear polymorphism (SNP) analysis in patients treated with anti-EGFR moAbs

Publication	SNP	n	Variable	Significance
Zhang et al[44]	FcγRIIa H131R, V158F	39	TTP	0.037
Bibeau et al[45]	FcγRIIa H131R, V158F	69	TTP	0.015
Graziano et al[46]	FcγRIIa H131R, V158F	110	RR, OS	NS
Nagashima et al[47]	FcγRIIa H131R, V158F	98	PFS	NS
Graziano et al[46]	EGFR in1 (CA)n repeats	110	RR, OS	0.006, 0.008
Gonçalves et al[52]	EGFR ex 13 R521K	32	PFS	0.020
Graziano et al[46]	EGF 61G/G	110	OS	0.001
Zhang et al[44]	cyclin-D1 870Α>G	39	TTP	0.019
Graziano et al[46]	cyclin-D1 870Α>G	110	RR, OS	NS
Nagashima et al[47]	cyclin-D1 870Α>G	98	PFS	NS

anti-EGFR: Anti-epidermal growth factor receptor; NS: Not significant.